CAR T therapy using blood immune cells for CD70 cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must test positive for CD70 on tumor tissue (a lab must confirm the result).
- Your cancer must be unresectable (can’t be fully removed by surgery); for Phase II it must also be measurable on scans.
- You must be an adult (18–72) and able to do daily activities fairly well (ECOG 0 or 1).
- You must have had at least one prior standard cancer treatment (or your cancer came back or didn’t respond).
- You may have up to 3 small, non-symptomatic brain metastases (and any treated ones must be stable after radiation).
- You must meet key blood and organ health requirements (immune, liver/kidney, and blood counts) and be well enough to consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (CAR-T cells) designed to attack cancer cells that have a protein called CD70. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
This trial tests a new treatment called CD70 CAR T cells, which are specially designed immune cells that target a protein called CD70 on cancer cells. It is for people with certain types of lymphoma, myeloma, kidney cancer, or sarcoma that has come back or not responded to other treatments.
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.